QuantHealth Achieves Impressive 8x Financial Growth Across Life Sciences Engagements

Audio By Carbonatix

TEL AVIV, Israel--(BUSINESS WIRE)--Mar 9, 2026--

QuantHealth, a pioneer in AI-driven clinical trial simulations, today announced a record year of growth, with sales increasing 8x through new and expanding engagements across life sciences organizations. This industry-leading pace of adoption reinforces the value of AI-driven clinical trial prediction to accelerate and simplify the costly, complex journey of bringing new drugs to market, while also identifying opportunities to improve the commercial impact of existing therapies.

In 2025, QuantHealth also established the industry’s most advanced clinical trial simulation portfolio – nearly doubling its clinical trial simulations to more than 600 trials – and achieving up to 90% accuracy across nearly 30 therapeutic areas, including oncology, respiratory, immunology, inflammation, cardiovascular and cardiometabolic diseases.

“This past year was pivotal for QuantHealth as we achieved unprecedented growth in bookings and revenue as a result of faster market penetration, larger client commitments and most exciting, through expansions across multiple pipelines for big pharma,” said Orr Inbar, CEO of QuantHealth. “These successes not only strengthen our position as a market leader in clinical trialsimulations, but signals that we’ve built an AI solution that has real, demonstrable value in the market.”

An estimated 90% of drugs fail in clinical trials, costing the pharmaceutical industry more than $50B annually, and delaying potentially life-saving therapies for patients. As a result, pharmaceutical leaders are increasingly looking to make faster and smarter clinical trial decisions. With QuantHealth’s predictive simulations, its clients can understand the safety and efficacy of medicines earlier, prioritize promising drug candidates for research, and predict patients’ responses to treatment before clinical trial initiation.

“QuantHealth has built unparalleled capabilities with a clear, long-term roadmap for innovation and deep AI adoption within main clinical development decisions that ensures we deliver sustained value to our clients and stakeholders now and in the future,” said the company’s Chief Strategy and Operations Officer Arnon Horev.

The company recently announced strategic investment from Sanofi Ventures, the venture capital arm of global healthcare leader Sanofi. The investment is accelerating the Company's efforts to bring scalable, patient-level simulations to the forefront of drug development.

To learn more about QuantHealth, please visit quanthealth.ai.

About QuantHealth

QuantHealth is the global leader for AI clinical trial simulation, bringing together the industry’s most advanced clinical trial simulations portfolio — 600+ trial simulations across 30 diseases with up to 90% prediction accuracy — and the category’s largest real-world data set to help life sciences and biotechnology organizations improve the potential of clinical trial successes. QuantHealth solutions use real-world data and predictive modeling to simulate trials at scale, optimize protocols, reduce risk, and accelerate timelines. The company is a trusted partner for twelve of the top 20 global pharmaceutical companies

View source version on businesswire.com:https://www.businesswire.com/news/home/20260309799009/en/

CONTACT: Mia Hinz

SolComms

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA ISRAEL MIDDLE EAST

INDUSTRY KEYWORD: BIOTECHNOLOGY DATA ANALYTICS PHARMACEUTICAL HEALTH ARTIFICIAL INTELLIGENCE PROFESSIONAL SERVICES TECHNOLOGY CLINICAL TRIALS

SOURCE: QuantHealth

Copyright Business Wire 2026.

PUB: 03/09/2026 02:55 PM/DISC: 03/09/2026 02:55 PM

http://www.businesswire.com/news/home/20260309799009/en